Metabolism; Molecular Imaging; Oncology; Radioactive Tracers
My research focuses on helping to understand the relevance of various cellular and metabolic pathways for proper organ function. Utilizing small amounts of a radioactively labeled substance, it is possible to image various receptors and a variety of peptides potentially involved in the metabolism and pathology of diseases and tumors in the field of nuclear medicine in which I work. Therefore, via molecular imaging targeting receptors and biochemical processes specifically involved in disease etiology and tumor pathogenesis, nuclear medicine plays a pivotal role in the field of endocrinology, oncology, cardiology, and brain metabolism.
Using the similar approach, but employing specific radionuclides suitable for therapy, radionuclide-labeled therapies have been developed that specifically target certain receptors that are overexpressed in certain disorder and tumor cells, thereby systemically destroying the local tumor and its distant metastases; a process called targeted theranostics.
Techniques, methods & infrastructure
Positron Emission Tomography-Computed Tomography/Magnetic Resonance Imaging employing various radio-labeled peptides targeting cells and specific receptors responsible for tumor and cellular metabolism at the molecular level.
- Rasul, S. et al. (2019) ‘Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks’, European Journal of Nuclear Medicine and Molecular Imaging, 47(3), pp. 713–720. Available at: http://dx.doi.org/10.1007/s00259-019-04584-1.
- Wollenweber, T. et al. (2021) ‘Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer’, Current Oncology, 28(5), pp. 3692–3704. Available at: http://dx.doi.org/10.3390/curroncol28050315.
- Zisser, L. et al. (2022) ‘Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases’, Nuclear Medicine Communications, 43(11), pp. 1113–1120. Available at: http://dx.doi.org/10.1097/mnm.0000000000001611.
- Rasul, S. et al. (2018) ‘[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery’, European Journal of Nuclear Medicine and Molecular Imaging, 45(12), pp. 2159–2169. Available at: http://dx.doi.org/10.1007/s00259-018-4045-9.
- Rasul, S. et al., 2020. Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI. BMJ Open Diabetes Research & Care, 8(1), p.e001135. Available at: http://dx.doi.org/10.1136/bmjdrc-2019-001135.